Head of Business Development
PhantomFull Time
Expert & Leadership (9+ years)
Candidates should possess a Bachelor’s degree in Information Systems, Business Administration, Finance, Economics, Mathematics, Operations Research, Marketing, or a related field, and a Master’s degree is preferred. They must have 10+ years of experience in business intelligence or data analytics, with at least 5 years in a leadership role, and a proven track record of managing BI teams and delivering complex analytics projects. Strong technical proficiency in BI tools such as Looker and data warehousing solutions like BigQuery, along with advanced SQL skills and a deep understanding of database modeling concepts, is required.
The Director of Business Intelligence will lead and manage a team of approximately 12 Business Intelligence (BI) professionals, fostering a culture of innovation and continuous improvement, and ensuring their work aligns with critical business initiatives. They will partner with cross-functional teams to identify BI needs and provide guidance and analytical support for developing new datasets and tools. The Director will also understand the complex business environment of Tempus AI, intersecting healthcare, genomics, and data science, and ensure BI initiatives align with the functions and needs of various departments. Furthermore, they will ensure adherence to data governance policies, support data management best practices, and stay abreast of emerging BI technologies, particularly in AI-driven analytics, to integrate AI tools and enhance productivity.
AI-driven healthcare data analysis platform
Tempus focuses on enhancing patient outcomes through the use of data and artificial intelligence in healthcare. The company offers a platform that analyzes medical data to provide insights for physicians, helping them make better treatment decisions. This platform also aids pharmaceutical and biotech companies in drug development by identifying new targets and assessing treatment effectiveness. For patients, Tempus identifies personalized therapy options, particularly in cancer care, where their research has shown increased opportunities for tailored treatments. They have developed a pan-cancer organoid platform and a liquid biopsy assay for profiling circulating tumor DNA. Tempus generates revenue by charging healthcare providers and companies for access to their platform and insights, setting them apart from competitors by their focus on personalized medicine and extensive cancer research.